Overview of current and future research and clinical directions for drug discontinuation: Psychological, traditional and professional obstacles to deprescribing

European Journal of Hospital Pharmacy

Volumn 24, Issue 1, 2017, Pages 16-20

  Garfinkel, Doron ^a,b  

^a Wolfson Medical Center   (Israel)

^b Israel Cancer Association   (Israel)

Author keywords

EDUCATION TRAINING (see Medical Education Training); PALLIATIVE CARE; PHARMACOTHERAPY; polypharmacy

Indexed keywords

CLINICAL OUTCOME; DEFENSIVE MEDICINE; DOCTOR PATIENT RELATION; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; GENERAL PRACTITIONER; HEALTH CARE MANAGEMENT; HUMAN; PATIENT SATISFACTION; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 85017120761     PISSN: 20479956     EISSN: 20479964     Source Type: Journal    
DOI: 10.1136/ejhpharm-2016-000959     Document Type: Review

References (45)

1. Garfinkel D, Ilhan B, Bahat G. Routine de-prescribing of chronic medications to combat polypharmacy. Ther Adv Drug Saf 2015;6:212-33.
2. Garfinkel D. Geriatric Boom Catastrophe-A major medical, economic and social nightmare of the 21st century [abstract]. Proc 6th. Congress Intern Ass Gerontol Geriatr 1997:364.
3. Garfinkel D. The tsunami in 21st century healthcare: the age-related vicious circle of co-morbidity-multiple symptoms-over-diagnosis-over treatment-polypharmacy. J Nutr Health Aging 2013;17(Suppl 1):SS24-227-C-1.
4. Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ 1997;315:1096-9.
5. Gill SS, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med 2005;165:808-13.
6. de Souto Barreto P, Ferrandez AM, Saliba-Serre B. Are older adults who volunteer to participate in an exercise study fitter and healthier than non volunteers? The participation bias of the study population. J Phys Act Health 2013;10:359-67.
7. Golomb BA, Chan VT, Evans MA, et al. The older the better: are elderly study participants more non-representative? A cross-sectional analysis of clinical trial and observational study samples. BMJ Open 2012;2:e000833.
8. Sugisawa H, Kishino H, Sugihara Y, et al. Characteristics of dropouts and participants in a twelve-year longitudinal research of Japanese elderly. Nihon Koshu Eisei Zasshi 2000;47:337-49. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? cmd=Retrieve&db=PubMed&dopt=Citation&list-uids=10835895
9. Hanlon JT, Schmader KE, Ruby CM, et al. Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc 2001;49:200-9.
10. Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol 2012;65:989-95.
11. Tinetti ME, Bogardus ST Jr, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med 2004;351:2870-4.
12. Nightingale G, Hajjar E, Swartz K, et al. Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. J Clin Oncol 2015;33:1453-9.
13. Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005;294:716-24.
14. Angell M. The Truth About Drug Companies: how they deceive us and what to do about it. New York: Random House, 2005.
15. Gotzsche P. Deadly medicines and organised crine. Radcliffe Medical Press, 2013.
16. Healy D. Pharmageddon. University of California Press, 2012.
17. Healy D, Cattell D. Interface between authorship, industry and science in the domain of therapeutics. Br J Psychiatry 2003;183:22-7.
18. Stavert RR, Lott JP. The bystander effect in medical care. N Engl J Med 2013;368:8-9.
19. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012;60:616-31.
20. O'Mahony D, O'Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing 2015;44:213-18.
21. Wehling M, Burkhardt H, Kuhn-Thiel A, et al. VALFORTA: a randomised trial to validate the FORTA (Fit fOR The Aged) classification. Age Ageing 2016;45:262-7.
22. Rudolph JL, Salow MJ, Angelini MC, et al. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008;168:508-13.
23. Hilmer SN, Mager DE, Simonsick EM, et al. Drug burden index score and functional decline in older people. Am J Med 2009;122:1142-9.e1141-1142.
24. Hanlon JT, Schmader KE. The medication appropriateness index at 20: where it started, where it has been, and where it May be going. Drugs Aging 2013;30:893-900.
25. ARMOR: A Tool to Evaluate Polypharmacy in Elderly Persons|Annals of Long Term Care. http://www.annalsoflongtermcare.com/content/armor-a-tool-evaluate-polypharmacyelderly-persons
26. Moorhouse P, Koller K, Mallery L. End of Life Care in Frailty. Interdiscip Top Gerontol Geriatr 2015;41:151-60.
27. Mallery LH, Ransom T, Steeves B, et al. Evidence-informed guidelines for treating frail older adults with type 2 diabetes: from the Diabetes Care Program of Nova Scotia (DCPNS) and the Palliative and Therapeutic Harmonization (PATH) program. J Am Med Dir Assoc 2013;14:801-8.
28. Moorhouse P, Mallery LH. Palliative and therapeutic harmonization: a model for appropriate decision-making in frail older adults. J Am Geriatr Soc 2012;60:2326-32.
29. Garfinkel D, Zur-Gil S, Ben-Israel J. The war against Polypharmacy. A new, cost Effective Geriatric-Palliative approach for improving drug therapy in disabled older people. Israel Med Assoc J 2007;9:430-4.
30. Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults. Addressing polypharmacy. Arch Int Med 2010;170:1648-54.
31. Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of de-prescribing. JAMA Intern Med 2015;175:827-34.
32. Sengstock D, Zimmerman J, Williams B, et al. Addressing polypharmacy & improving medication adherence in older adults. Eds: Brie A Williams, Anna Chang, Cyrus Ahalt, Helen Chen, Rebecca Conant, C Seth Landefeld, Christina Ritchie, Michi Yukawa. In: Current diagnosis and treatment: geriatrics 2e. McGraw-Hill Education/Medical, 2014:608.
33. Reeve E, Shakib S, Hendrix I, et al. Review of de-prescribing processes and development of an evidence-based, patient-centred de-prescribing process. Br J Clin Pharmacol 2014;78:738-47.
34. Linsky A, Simon SR, Bokhour B. Patient perceptions of proactive medication discontinuation. Patient Educ Couns 2015;98:220-5.
35. Reeve E, Turner JP. Patients' perspectives on the brave new word 'de-prescribing'. Int J Pharm Pract 2015;23:90-1.
36. Scott IA, Anderson K, Freeman CR, et al. First do no harm: a real need to de-prescribe in older patients. Med J Aust 2014;201:390-2.
37. Plakiotis C, Bell JS, Jeon Y-H, et al. Deprescribing psychotropic medications in aged care facilities: The potential role of family members. Adv Exp Med Bio 2015;821:29-43.
38. Nixon M. Organising medication discontinuation: GP decision making when de-prescribing statins. Denmark: Copenhagen University, 2014.
39. Schuling J, Gebben H, Veehof LJ, et al. Deprescribing medication in very elderly patients with multimorbidity: the view of Dutch GPs. A qualitative study. BMC Fam Pract 2012;13:56.
40. Anderson K, Stowasser D, Freeman C, et al. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open 2014;4:e006544.
41. Ostini R, Hegney D, Jackson C, et al. Knowing how to stop: ceasing prescribing when the medicine is no longer required. J Manag Care Pharm 2012;18:68-72.
42. Reeve E, To J, Hendrix I, et al. Patient Barriers to and Enablers of De-prescribing: a Systematic Review. Drugs Aging 2013;30:793-807.
43. Salazar JA, Poon I, Nair M, et al. linical consequences of polypharmacy in elderly: expect the unexpected, think the unthinkable. Expert Opin Drug Saf 2007;6:695-704.
44. Steinman MA, Rosenthal GE, Landefeld CS, et al. Agreement between drugs-to-avoid criteria and expert assessments of problematic prescribing. Arch Intern Med 2009;169:1326-32.
45. Sackett, DL, Rosenberg WMC, Gray JAM, et al. Evidence based medicine: what it is and what it isn't. BMJ 1996;312:71-2.